Latest Global Markets News

Pointerra Limited reported a stronger Q1 FY26 with nearly A$2 million in customer receipts and advancing AI-powered digital twin solutions across key sectors, setting the stage for improved cash flow and expanded market presence.

Toro Energy has agreed to be acquired by IsoEnergy in a deal valuing Toro shares at a 79.7% premium, combining uranium assets across Australia, Canada, and the US. The transaction promises enhanced scale and exposure to tier-one uranium projects, pending shareholder and regulatory approvals.

Renascor Resources has commenced construction of its government-backed Purified Spherical Graphite demonstration plant in Adelaide, while securing key land and expanding exploration amid shifting global graphite supply dynamics.

Evion Group advances its Maniry Graphite Project in Madagascar and expandable graphite JV in India, backed by a strategic US investor and EU recognition. The company is poised to expand production and supply critical minerals to key global markets amid rising demand.

Basin Energy has acquired NeoDys Limited, gaining a substantial uranium and rare earth exploration package in Queensland, and launched a $1.25 million capital raise to fund maiden drilling in late 2025.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Uscom Limited reported a 27% drop in cash reserves for Q1 2025, driven by declining revenue and rising costs, while preparing to sell its main business unit to stabilize finances.

Surefire Resources reports robust drilling results at its Yidby Gold Project alongside promising assays from its Victory Bore critical minerals deposit, supported by a $1.54 million capital raise.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug candidate NUZ-001 and strengthened its balance sheet with a $5.2 million capital raise. The company is now poised to enter the pivotal HEALEY ALS Platform Trial, marking a significant step forward in its neurodegenerative disease program.

Larvotto Resources has greenlit the Hillgrove Antimony-Gold Project development, securing $175 million in funding and reporting strong high-grade drilling results that bolster its resource base.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.